ATE277068T1 - 2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind - Google Patents

2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind

Info

Publication number: ATE277068T1
Authority: AT; Austria
Prior art keywords: rns; conformally; restricted; action; modified oligonucleotides
Prior art date: 1998-07-27

Application number

AT99935814T

Other languages

English (en)

Inventor

Muthiah Manoharan

Venkatraman Mohan

Herb Boswell

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-27

Filing date

1999-07-21

Publication date

2004-10-15

1999-07-21 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2004-10-15 Application granted granted Critical

2004-10-15 Publication of ATE277068T1 publication Critical patent/ATE277068T1/de

Links

JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 3
239000002777 nucleoside Substances 0.000 abstract 2
125000003835 nucleoside group Chemical group 0.000 abstract 2
108091034117 Oligonucleotide Proteins 0.000 abstract 1
238000000302 molecular modelling Methods 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99935814T 1998-07-27 1999-07-21 2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind ATE277068T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/123,108 US6271358B1 (en)	1998-07-27	1998-07-27	RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
PCT/US1999/016541 WO2000006590A1 (en)	1998-07-27	1999-07-21	Rna targeted 2'-modified oligonucleotides that are conformationally preorganized

Publications (1)

Publication Number	Publication Date
ATE277068T1 true ATE277068T1 (de)	2004-10-15

Family

ID=22406758

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99935814T ATE277068T1 (de)	1998-07-27	1999-07-21	2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind

Country Status (6)

Country	Link
US (1)	US6271358B1 (de)
EP (1)	EP1100809B1 (de)
AT (1)	ATE277068T1 (de)
AU (1)	AU5121399A (de)
DE (1)	DE69920477D1 (de)
WO (1)	WO2000006590A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6824976B1 (en)	1993-04-02	2004-11-30	Rigel Pharmaceuticals, Inc.	Method for selective inactivation of viral replication
US6639061B1 (en)	1999-07-07	2003-10-28	Isis Pharmaceuticals, Inc.	C3′-methylene hydrogen phosphonate oligomers and related compounds
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US6576752B1 (en) *	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
US6326478B1 (en)	1998-07-08	2001-12-04	Isis Pharmaceuticals, Inc.	Process for the synthesis of oligomeric compounds
US6277967B1 (en)	1998-07-14	2001-08-21	Isis Pharmaceuticals, Inc.	Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
DE19956568A1 (de) *	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6465628B1 (en)	1999-02-04	2002-10-15	Isis Pharmaceuticals, Inc.	Process for the synthesis of oligomeric compounds
US6121437A (en) *	1999-03-16	2000-09-19	Isis Pharmaceuticals, Inc.	Phosphate and thiophosphate protecting groups
US20040082774A1 (en) *	1999-03-16	2004-04-29	Guzaev Andrei P.	Novel phosphate and thiophosphate protecting groups
US6610842B1 (en) *	1999-05-06	2003-08-26	Isis Pharmaceuticals, Inc.	Processes for the synthesis of oligomers using phosphoramidite compositions
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6593466B1 (en) *	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
US6617442B1 (en) *	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
DE10100586C1 (de) *	2001-01-09	2002-04-11	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Ziegens
US7423142B2 (en) *	2001-01-09	2008-09-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
WO2004043979A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7276599B2 (en)	2003-06-02	2007-10-02	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
CN1984921B (zh)	2003-06-03	2010-06-16	Isis药物公司	存活蛋白表达的调节
WO2005014782A2 (en)	2003-06-13	2005-02-17	Alnylam Europe Ag.,	Double-stranded ribonucleic acid with increased effectiveness in an organism
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
KR101147147B1 (ko)	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
CA2562151C (en)	2004-04-30	2016-09-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a c5-modified pyrimidine
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7427675B2 (en) *	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
US20060166234A1 (en)	2004-11-22	2006-07-27	Barbara Robertson	Apparatus and system having dry control gene silencing compositions
US7935811B2 (en)	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
WO2007027775A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
DK1931780T3 (en)	2005-08-29	2016-01-25	Regulus Therapeutics Inc	Antisense-forbindelser med forøget anti-microrna-aktivitet
AU2006305886C1 (en)	2005-10-28	2011-03-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
WO2007056326A2 (en) *	2005-11-04	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of nav1.8 gene
WO2007056331A2 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
US8129515B2 (en)	2006-01-27	2012-03-06	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
US8809514B2 (en)	2006-09-22	2014-08-19	Ge Healthcare Dharmacon, Inc.	Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
EP2247729B1 (de)	2008-02-11	2019-05-01	Phio Pharmaceuticals Corp.	Modifizierte rnai-polynukleotide und verwendungen davon
US8846639B2 (en) *	2008-04-04	2014-09-30	Isis Pharmaceutical, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
CA2728467A1 (en) *	2008-07-15	2010-01-21	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
EP2340309A2 (de)	2008-09-22	2011-07-06	Rxi Pharmaceuticals Corporation	Neutrale nanotransporter
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
RU2011124146A (ru) *	2008-11-17	2012-12-27	Ф.Хоффманн-Ля Рош Аг	Композиции и способы подавления экспрессии генов фактора vii
US9074211B2 (en)	2008-11-19	2015-07-07	Rxi Pharmaceuticals Corporation	Inhibition of MAP4K4 through RNAI
US9493774B2 (en)	2009-01-05	2016-11-15	Rxi Pharmaceuticals Corporation	Inhibition of PCSK9 through RNAi
BRPI1008109A2 (pt) *	2009-02-03	2015-08-25	Hoffmann La Roche	"composições e métodos para a inibição de expressão de genes de ptp1b".
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
AU2010247389A1 (en) *	2009-05-15	2011-10-27	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of glucocorticoid receptor (GCR) genes
AR078921A1 (es) *	2009-11-09	2011-12-14	Hoffmann La Roche	Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
US20110152349A1 (en)	2009-12-18	2011-06-23	Anke Geick	Compositions and methods for inhibiting expression of il-18 genes
TW201129365A (en)	2010-02-05	2011-09-01	Hoffmann La Roche	Compositions and methods for inhibiting expression of IKK2 genes
BR112012024049A2 (pt)	2010-03-24	2017-03-01	Rxi Pharmaceuticals Corp	interferência de rna em indicações dérmicas e fibróticas
EP2550000A4 (de)	2010-03-24	2014-03-26	Advirna Inc	Selbstfreisetzende rnai-verbindungen von reduzierter grösse
CN106074591B (zh)	2010-03-24	2020-01-14	菲奥医药公司	眼部症候中的rna干扰
WO2012052258A1 (en)	2010-10-18	2012-04-26	Arrowhead Research Corporation	Compositions and methods for inhibiting expression of rrm2 genes
JP6165723B2 (ja)	2011-06-30	2017-07-19	アローヘッドファーマシューティカルズインコーポレイテッド	Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
KR102298475B1 (ko)	2013-10-04	2021-09-06	노파르티스 아게	ＲＮＡ 간섭에 사용하기 위한 ＲＮＡｉ 작용제를 위한 3' 말단 캡
EP3052627B1 (de)	2013-10-04	2018-08-22	Novartis AG	Neuartige formate für organische verbindungen zur verwendung bei rna-interferenz
JP6546161B2 (ja)	2013-10-04	2019-07-17	ノバルティスアーゲー	Ｂ型肝炎ウイルスを治療するための有機化合物
CN106061488B (zh)	2013-12-02	2021-04-09	菲奥医药公司	癌症的免疫治疗
US11279934B2 (en)	2014-04-28	2022-03-22	Phio Pharmaceuticals Corp.	Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
TW201620526A (zh)	2014-06-17	2016-06-16	愛羅海德研究公司	用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
KR102506169B1 (ko)	2014-09-05	2023-03-08	피오 파마슈티칼스 코프.	Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
US11001845B2 (en)	2015-07-06	2021-05-11	Phio Pharmaceuticals Corp.	Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
KR20180038465A (ko)	2015-08-07	2018-04-16	애로우헤드 파마슈티컬스 인코포레이티드	Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
CN109563509B (zh)	2015-10-19	2022-08-09	菲奥医药公司	靶向长非编码rna的减小尺寸的自递送核酸化合物
KR20190031306A (ko)	2016-07-21	2019-03-25	맥스시티 인코포레이티드	게놈 dna를 변경하기 위한 방법 및 조성물
JOP20190015A1 (ar)	2016-08-04	2019-02-04	Arrowhead Pharmaceuticals Inc	عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
UY37565A (es)	2017-01-10	2018-07-31	Arrowhead Pharmaceuticals Inc	Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso
JP7167059B2 (ja)	2017-04-19	2022-11-08	フィオファーマシューティカルズコーポレーション	核酸化合物の局所送達
EP3790970A1 (de)	2018-05-07	2021-03-17	Alnylam Pharmaceuticals Inc.	Extrahepatische verabreichung
EP3980540A4 (de)	2019-06-06	2023-11-01	Arrowhead Pharmaceuticals, Inc.	Verfahren zur behandlung von alpha-1-antitrypsin-mangel (aatd)
US20220305117A1 (en)	2019-06-18	2022-09-29	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
WO2020255008A1 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
CN116606336B (zh) *	2022-04-02	2025-09-12	思合基因(北京)生物科技有限公司	高稳定性和亲和力的2′-o-取代核苷及其应用
WO2023233290A1 (en)	2022-05-31	2023-12-07	Janssen Sciences Ireland Unlimited Company	Rnai agents targeting pd-l1
WO2024097674A2 (en) *	2022-11-02	2024-05-10	Aligos Therapeutics, Inc.	Modified short interfering nucleic acid (sina) molecules and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
GB8607265D0 (en) *	1986-03-24	1986-04-30	London King S College	Protecting groups of organic synthesis
US5216141A (en)	1988-06-06	1993-06-01	Benner Steven A	Oligonucleotide analogs containing sulfur linkages
WO1990003881A1 (en) *	1988-10-10	1990-04-19	G.D. Engineering Pty. Limited	Pre-stretching wrapping film
US5109126A (en) *	1988-12-06	1992-04-28	Worcester Foundation For Experimental Biology	5'[2'(3')-O-(2,4,6-trinitrophenyl) pyprimidine nucleoside]diphosphate 1-glycosides
US5212295A (en)	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US6369209B1 (en) *	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5438130A (en) *	1993-01-15	1995-08-01	Cambridge Neuroscience, Inc.	Fucosylated guanosine disulfates as excitatory amino acid antagonists
US5858988A (en) *	1993-02-24	1999-01-12	Wang; Jui H.	Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
CN1078478C (zh) *	1993-02-24	2002-01-30	王瑞駪	活性抗病毒聚合物的组成及应用方法

1998
- 1998-07-27 US US09/123,108 patent/US6271358B1/en not_active Expired - Lifetime
1999
- 1999-07-21 DE DE69920477T patent/DE69920477D1/de not_active Expired - Lifetime
- 1999-07-21 EP EP99935814A patent/EP1100809B1/de not_active Expired - Lifetime
- 1999-07-21 AU AU51213/99A patent/AU5121399A/en not_active Abandoned
- 1999-07-21 AT AT99935814T patent/ATE277068T1/de not_active IP Right Cessation
- 1999-07-21 WO PCT/US1999/016541 patent/WO2000006590A1/en not_active Ceased

Also Published As

Publication number	Publication date
AU5121399A (en)	2000-02-21
WO2000006590A1 (en)	2000-02-10
EP1100809B1 (de)	2004-09-22
US6271358B1 (en)	2001-08-07
EP1100809A1 (de)	2001-05-23
EP1100809A4 (de)	2002-02-27
DE69920477D1 (de)	2004-10-28

Legal Events

Date	Code	Title	Description
2005-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69920477D1 (de)	2004-10-28	2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind
DE69806003D1 (de)	2002-07-18	Dna polymerasen, die verbesserte fähigkeiten zum einbau markierter nukleotide besitzen
EP1102787A4 (de)	2001-09-19	2'-o-aminoethyloxyethyl-modifizierte oligonukleotide
ATE154029T1 (de)	1997-06-15	7-deazapurin modifizierte oligonukleotide
WO2005026184A3 (en)	2007-02-01	Synthesis and compositions of 2'-terminator nucleotides
CA2153898A1 (en)	1994-07-21	Method for generating single-stranded dna molecules
DK1178999T3 (da)	2007-08-06	L-RIBO-LNA-analoger
ATE373671T1 (de)	2007-10-15	Aminooxy-modifizierte oligonukleotide
ATE225369T1 (de)	2002-10-15	Doppelsträngige peptidenukleinsäuren
CA2167361A1 (en)	1996-07-19	2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
DE69736840D1 (de)	2006-11-30	Synthese von nukleosiden und polynukleotiden
BR9401355A (pt)	1994-10-18	Oligonucleotídeo e nucleotídeo.
BR9808730B1 (pt)	2009-01-13	processo de preparação de 1,1,1,3,3-pentaclorobutano.
MA26460A1 (fr)	2004-12-20	Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent.
ZA9811833B (en)	1999-07-20	Pharmaceutical compositions of uridine triphosphate.
EP1023310A4 (de)	2001-05-16	Synthese von sulfurierten oligonukleotiden
ZA961082B (en)	1997-08-11	DNA sequence.
ATE369429T1 (de)	2007-08-15	Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen
EP1019092A4 (de)	2004-12-15	Therapeutische und diagnostische mittel für krankheiten mit gestörter glukose-toleranz
NO970885D0 (no)	1997-02-27	Oligonukleotid konjugater, sammensetninger og fremgangsmåter for splitting av ribonukleotider
DE69726276D1 (de)	2003-12-24	In situ herstellung von nukleosid-phosphoramiditen und ihre verwendung in der oligonukleotidsynthese
MX9800339A (es)	1998-09-30	Preparacion in situ de nucleosido fosforamiditas y sintesis de oligonucleotido.
DK0970030T3 (da)	2003-08-04	Fremgangsmåde til at oprense 1,3,5-triisopropylbenzen
FR2721617B1 (fr)	1996-09-06	Fragments d'acides nucléiques, dérivés du génome de Mycobacterium xenopi et leurs applications.
MX9709596A (es)	1998-03-29	Adn catal ??tico.